MedicineNews.net - Medical Updates

Loncastuximab tesirine in patients with relapsed or refractory diffuse large b-cell lymphoma

Positive results from the pivotal 145-patient phase 2 clinical trial of Loncastuximab tesirine ( ADCT-402 ) for the treatment of relapsed or refractory diffuse large B-cell lymphoma ( DLBCL ) were an ... read article

Nivolumab plus Ipilimumab has shown continued survival benefit at 42-month follow-up in patients with previously untreated advanced or metastatic renal cell carcinoma

Updated results from the phase 3 CheckMate -214 study evaluating the combination of Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) versus Sunitinib( Sutent ) in patients with previously untreated adv ... read article

Muscle-invasive urothelial cancer: Atezolizumab as adjuvant monotherapy treatment did not meet its primary endpoint in IMvigor010

The phase III IMvigor010 study evaluating Atezolizumab ( Tecentriq ) as an adjuvant ( after surgery ) monotherapy treatment did not meet its primary endpoint of disease-free survival ( DFS ) compared ... read article

FIREFISH trial in infants with type 1 spinal muscular atrophy: Risdiplam has demonstrated motor improvement

Positive results from the pivotal Part 2 of the FIREFISH study, evaluating Risdiplam in infants aged 1-7 months with type 1 spinal muscular atrophy ( SMA ) were announced. The primary outcome measu ... read article

Keytruda in patients with high-risk, non-muscle invasive bladder cancer

The FDA ( U.S. Food and Drug Administration ) has accepted and granted priority review for a new supplemental Biologics License Application ( sBLA ) for Keytruda ( Pembrolizumab ), an anti-PD-1 therap ... read article

Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment

The EMA's Committee for Medicinal Products for Human Use ( CHMP ) has recommended the approval of Kadcyla ( Trastuzumab emtansine ) for the adjuvant treatment of adult patients with HER2-positive earl ... read article

Revlimid in combination with Rituximab for the treatment of adult patients with previously treated follicular lymphoma

The European Medicines Agency's ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the approval of Revlimid ( Lenalidomide ) in combination wi ... read article

Mayzent for the treatment of adult patients with active secondary progressive multiple sclerosis: CHMP has granted positive opinion

The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion for Mayzent ( Siponimod ) for the treatment of adult patients with s ... read article

Metastatic or unresectable recurrent head and neck squamous cell carcinoma: Keytruda, as monotherapy or in combination with Platinum and 5-Fluorouracil chemotherapy, in patients whose tumors express PD-L1

The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion recommending approval of two regimens of Keytruda ( Pembrolizumab ), ... read article

Atezolizumab in combination with Bevacizumab has increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma

The phase III IMbrave150 study, evaluating Atezolizumab ( Tecentriq ) in combination with Bevacizumab ( Avastin ) as a treatment for people with unresectable hepatocellular carcinoma ( HCC ) who have ... read article

Ixekizumab superior to Guselkumab in people with moderate to severe plaque psoriasis

Data were presented at the 5th Annual Maui Derm NP+PA Fall meeting from the phase 4 IXORA-R study, the first head-to-head ( H2H ) study between an IL-17A inhibitor and an IL-23/p19 inhibitor using the ... read article

TRK fusion cancer: updated analysis for Larotrectinib has confirmed high response rate and durable responses over three years in children and adults

Updated clinical data for Larotrectinib ( Vitrakvi ) in adult and pediatric patients with TRK fusion cancer showed a high response rate with an overall response rate ( ORR ) of 79% ( 95% CI: 72–85 ) w ... read article

ATLAS-2M trial: similar efficacy of Cabotegravir and Rilpivirine administered every eight weeks compared to four-week administration

Positive results from global phase III ATLAS-2M study of the investigational, long-acting, injectable, 2-drug regimen ( 2DR ) of Cabotegravir and Rilpivirine for the treatment of HIV were announced. ... read article

Pooled five-year survival results for Nivolumab in previously-treated advanced non-small cell lung cancer patients

Long-term pooled efficacy and safety results from the phase 3 CheckMate -017 and CheckMate -057 studies in patients with previously treated advanced non-small cell lung cancer ( NSCLC ) were announced ... read article

5-year open-label treatment period: data have confirmed long-term efficacy and safety of Erenumab

During the OLTP ( open-label treatment period ), Erenumab ( Aimovig ) was not only able to reduce monthly migraine days, but also decrease the number of days requiring acute migraine-specific medicati ... read article